Pharmacological agents in development for diabetic macular edema

Basit Öğe Kaydı
dc.contributor.authorSadiq, M.A.
dc.contributor.authorHalim, M.S.
dc.contributor.authorHassan, M.
dc.contributor.authorOnghanseng, N.
dc.contributor.authorKaraca, I.
dc.contributor.authorAgarwal, A.
dc.contributor.authorNguyen, Q.D.
dc.date.accessioned2020-12-01T11:52:34Z
dc.date.available2020-12-01T11:52:34Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Diabetic macular edema (DME) is the leading cause of visual loss in patients with diabetic retinopathy. There has been a paradigm shift in the treatment of DME since the advent of anti-vascular endothelial growth factor (anti-VEGF) therapy. The safety and efficacy of anti-VEGF therapy has been well established. Although efficacious, currently approved anti-VEGF agents are associated with certain limitations, which include, among others: frequent need for injections, high treatment cost and variable response to treatment. These challenges have led to an active search for more novel agents that may be able to overcome these limitations. Areas covered: The index review focuses on novel treatment agents that target various pathways in patients with DME. These agents are used either as monotherapy or in combination with other agents in the management of DME. Drugs discussed include novel anti-VEGF inhibitors, TIE-2 receptor modulators, integrin peptide inhibitors, rho kinase inhibitors, and future therapies such as neuroprotection and gene therapy. Conclusions: The future of investigational pharmacological therapy appears promising for patients with DME. Results from early clinical trials indicate that newer agents highlighted in the study may be safe and efficacious treatment options for patients with DME. However, data from large multicenter clinical trials need to be analyzed before these agents can be incorporated into clinical practice. © 2020 The Author(s).en_US
dc.identifier.doi10.1186/s40942-020-00234-z
dc.identifier.issn2056-9920
dc.identifier.issn2056-9920en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85088503761en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1186/s40942-020-00234-z
dc.identifier.urihttps://hdl.handle.net/11454/61579
dc.identifier.volume6en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBioMed Central Ltden_US
dc.relation.ispartofInternational Journal of Retina and Vitreousen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiabetic macular edemaen_US
dc.subjectDiabetic retinopathyen_US
dc.subjectVascular endothelial growth factoren_US
dc.titlePharmacological agents in development for diabetic macular edemaen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu